Project Grant R43EY035872
Award Date
9/30/24
Completion Date
8/31/25
Dollars Obligated
$590K
Federal Agency
National Eye Institute
Awardee
Vyluma Inc. (PWS6ABAWL9U5)
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
New Jersey, USA
Similar Awards
This $1,559,917 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to develop a topical neurokinin-1 receptor (NK1R) antagonist as a non-addictive analgesic treatment for chronic ocular pain. The key objectives are to assess the analgesic efficacy of the NK1R antagonist and determine its effects on the ocular surface-trigeminal ganglion neurosensory pathway. The project is...
This Project Grant award from the National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), aims to advance the development of the drug filociclovir (FCV) for the treatment of adenoviral conjunctivitis and epidemic keratoconjunctivitis. The $674,963 award to Microbiotix, Inc. will fund the completion of key preclinical activities, including finalizing the eye drop formulation, conducting IND-enabling toxicology studies in rabbits and rats, and completing regulatory...
The National Eye Institute (NEI) awarded a $578,123 Project Grant (CFDA 93.867 - Vision Research) to the Regents of the University of Michigan to conduct a comprehensive study on central nervous system mechanisms and treatment response in chronic ocular surface pain (COSP). The 5-year research project aims to rigorously define the role of nociplastic (centralized) pain in COSP, which affects 5-15% of the U.S. population at an estimated annual cost of over $55 billion. The study will utilize...
This Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) provides $1,066,178 to Tavo Biotherapeutics, Inc. (operating as Oculo Therapy LLC) to support late-stage preclinical development and GMP production of a novel extended-release intraocular pressure (IOP)-lowering formulation for the treatment of glaucoma. The funding will enable critical IND-enabling studies for this first-in-class drug candidate using the FDA-approved drug pregabalin as...
This Project Grant award from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), supports research to understand the development and function of corneal lens-secreting cells in the human eye. The $543,037 award, effective September 1, 2024 through May 31, 2028, will fund investigations into the genetic and molecular mechanisms underlying corneal development and function. Key research objectives include identifying transcription factors and...
This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides funding of $1,426,622 to The Washington University to conduct research on the neural mechanisms underlying corneal injuries caused by ammonia exposure. The key objectives are to: Correlate the delayed corneal wound regeneration with the extent of corneal nerve degradation in mouse models, and quantify the associated ocular pain behaviors. Delineate the activating mechanism of corneal sensory...
This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides $615,979 to Wayne State University to investigate a promising peptide-based combination therapy that targets hyperglycemia-responsive circuits in the cornea to prevent high glucose-induced damage and restore structure and function in the diabetic cornea. The award supports in vitro and in vivo assessments to establish the therapeutic role of the TB4 and VIP combination treatment and elucidate the...
This Project Grant award from the National Eye Institute (CFDA 93.867 Vision Research) supports the development and validation of a nanoparticle-based therapy called TRE-D-DASA to treat corneal neovascularization (CONV), a sight-threatening condition characterized by abnormal blood vessel growth in the cornea. The $482,067 award will fund research to: 1) synthesize and characterize the TRE-D-DASA conjugate and a fluorescent version for imaging; 2) assess the biodistribution, pharmacokinetics,...
The National Eye Institute (NEI) awarded a $586,258 Project Grant under the Vision Research program (CFDA 93.867) to Wayne State University to conduct research on the role of eosinophils in modulating the corneal response to Pseudomonas aeruginosa infection. The research, spanning from Jul 1, 2025 to Apr 30, 2029, aims to characterize the spatiotemporal distribution, phenotypic profiles, and proteomic changes of eosinophils during corneal inflammation and infection using mouse models. The...
This $185,000 Project Grant award from the National Eye Institute (NEI) under CFDA 93.867 (Vision Research) supports research to discover novel disease-modifying therapies for the prevention and treatment of glaucoma. The primary awardee, the University of North Texas Health Science Center at Fort Worth, will employ computational pharmacology approaches to identify small molecule inhibitors that can interfere with the GREM1-BMP protein-protein interaction, a key pathogenic mechanism contributing...